🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Recruitingn/aAges 18 Years - anyAllMethodist Health System
NCT06223607 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * ≥ 18 years * PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021) * Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI * At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor Exclusion Criteria: * Death within 48 hours post-PCI * DAPT prior to cardiac catheterization
💊

What it tests

  • Not listed
📍

Where

1 site
Methodist Dallas Medical Center
Dallas, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy